Pfizer (NYSE:PFE) gains with 7% yield as China trial faces questions

Pfizer Inc. ticked up on Monday, rising after a move in China increased reimbursement for its GLP-1 offering, giving it another inroad into the market. Shares added 0.4% to $24.37 late in New York trading, but trailed a broader rally. The S&P 500 ended up 1.18% at 7,440.43, and the Nasdaq Composite jumped 2.07%.

Pfizer Inc. shares fell on Tuesday. The company said a key lung cancer drug from its Seagen unit didn’t hit the main endpoint in a late-stage study. That’s another setback for Pfizer as it tries to spark growth again after its COVID-era products.

Pfizer Inc. shares slid again after its CFO said he’ll step down in August. The stock closed at $25.21, losing 2.7% on Thursday before the Juneteenth holiday and the weekend.

Pfizer dropped 2.7% to $25.21 Thursday, closing out a short week lower after its CFO said he is leaving. The news raised questions about Pfizer’s 2026 outlook and its post-pandemic turnaround. U.S. markets shut Friday for Juneteenth.

Pfizer shares dropped on Thursday after the drugmaker said finance chief Dave Denton would leave in August, a management change that hit a stock already being judged on a long and expensive growth rebuild.

Pfizer Inc. shares added 0.36% to trade around $26.27 Friday, putting its market cap at roughly $150.5 billion. The stock had climbed 2.23% Thursday, closing at $26.17, on higher-than-average volume and outperforming most major health-care names, MarketWatch said. Broader markets were higher Friday, with the SPDR S&P 500 ETF Trust up, but the Health Care Select Sector SPDR ETF was down a bit, showing Pfizer trading better than the sector in late-morning deals.

• Pfizer stock rose about 2.7% to around $26.28 in late Thursday trading.• RBC Capital moved its rating on Pfizer up to Sector Perform from Underperform, sticking with the $25 target.• Reuters said new German drug-pricing plans are adding another risk for global pharma companies.

Pfizer Inc. shares fell in premarket trading Tuesday after the FDA cleared a new label for its hemophilia treatment Hympavzi. Investors are still sizing up the company’s longer path to profits in obesity drugs. The stock traded at $25.62, off 43 cents, or 1.7%.